CLCA2_Clac2 Inhibitors
CLCA2 (Calcium-activated chloride channel regulator 2), also known as CLAC2 (Chloride channel accessory 2), inhibitors are a class of chemical compounds that specifically target and modulate the activity of the CLCA2/CLAC2 protein. CLCA2 is a member of the CLCA family of proteins, which are primarily involved in the regulation of calcium-activated chloride channels. These channels play a significant role in various physiological processes, including electrolyte balance, fluid secretion, and mucin production. CLCA2 itself is expressed in various tissues, including the respiratory epithelium and colon, suggesting its involvement in mucosal integrity and respiratory functions. CLCA2/CLAC2 inhibitors are designed to interact with the CLCA2 protein and modulate its function, possibly by affecting its regulation of chloride channels or its interaction with other cellular components.
By targeting CLCA2, these inhibitors have the ability to impact chloride ion transport, cellular homeostasis, and other relevant cellular processes. Their selectivity towards CLCA2 makes them valuable tools for studying the specific functions of this protein in various tissues and systems. The development of CLCA2 inhibitors represents an ongoing area of research in molecular pharmacology, with scientists aiming to understand the intricate molecular mechanisms behind CLCA2's involvement in chloride channel regulation. Through the design and synthesis of these inhibitors, researchers can explore the roles of CLCA2 in normal physiology and investigate its ability relevance in pathological conditions. The intricate interplay between CLCA2 and chloride channel function underscores the importance of this class of inhibitors in unraveling the complexities of cellular signaling and ion transport mechanisms.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil is a calcium channel blocker that inhibits CLCA2/CLAC2 by blocking L-type calcium channels in smooth muscle cells, reducing intracellular calcium levels and leading to relaxation of airway smooth muscles. This helps alleviate symptoms of asthma and other airway disorders. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Nifedipine, a calcium channel blocker, acts on L-type calcium channels, including those in airway smooth muscle cells, inhibiting CLCA2/CLAC2. By reducing intracellular calcium levels, it promotes bronchodilation, making it useful for managing airway constriction. | ||||||
Amlodipine | 88150-42-9 | sc-200195 sc-200195A | 100 mg 1 g | $74.00 $166.00 | 2 | |
Amlodipine is a calcium channel blocker that targets L-type calcium channels. Its mechanism involves inhibiting CLCA2/CLAC2, leading to decreased intracellular calcium levels in airway smooth muscle cells and promoting relaxation, thus aiding in respiratory conditions. | ||||||
Felodipine | 72509-76-3 | sc-201483 sc-201483A | 10 mg 50 mg | $91.00 $222.00 | 1 | |
Felodipine acts as a calcium channel blocker targeting L-type calcium channels. Its action inhibits CLCA2/CLAC2, resulting in decreased intracellular calcium levels in airway smooth muscle cells, contributing to bronchodilation and improved airway function. | ||||||
Isradipine | 75695-93-1 | sc-201467 sc-201467A | 10 mg 50 mg | $88.00 $324.00 | 1 | |
Isradipine targets L-type calcium channels, inhibiting CLCA2/CLAC2. By reducing calcium influx into airway smooth muscle cells, it helps relax the bronchial muscles, making it valuable for respiratory disorders characterized by airway constriction. | ||||||
Nimodipine | 66085-59-4 | sc-201464 sc-201464A | 100 mg 1 g | $61.00 $307.00 | 2 | |
Nimodipine acts as a calcium channel blocker that targets L-type calcium channels. Its mechanism involves inhibiting CLCA2/CLAC2, leading to bronchodilation due to decreased intracellular calcium levels in airway smooth muscle cells. | ||||||
trans Lacidipine | 103890-78-4 | sc-213066 | 10 mg | $153.00 | ||
Lacidipine inhibits CLCA2/CLAC2 by acting on L-type calcium channels in airway smooth muscle cells. This results in reduced intracellular calcium levels, leading to relaxation of bronchial muscles and contributing to the management of airway constriction. | ||||||
Manidipine | 89226-50-6 | sc-211774 | 10 mg | $278.00 | ||
Manidipine is a calcium channel blocker that targets L-type calcium channels, inhibiting CLCA2/CLAC2. Its mechanism involves reducing intracellular calcium levels, leading to relaxation of airway smooth muscle cells and improved respiratory function. | ||||||